Tyrosine protein kinase inhibitors prevent activation of cardiac swelling-induced chloride current

S Sorota1

  • 1Department of Pharmacology, Columbia University, New York, NY 10032, USA.

Insights

Tyrosine protein kinase inhibitors, like genistein, can block swelling-induced chloride currents (ICl-swelling) in dog heart cells. This suggests tyrosine phosphorylation is crucial for activating these currents.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Cell Physiology

Background:

  • Swelling-activated chloride currents (ICl-swelling) play a role in cell volume regulation.
  • The precise molecular mechanisms activating ICl-swelling remain incompletely understood.
  • Tyrosine protein kinases are implicated in various cellular signaling pathways.

Purpose of the Study:

  • To investigate the role of tyrosine protein kinase inhibitors in modulating ICl-swelling in dog atrial myocytes.
  • To elucidate the involvement of tyrosine phosphorylation in the activation of ICl-swelling.

Main Methods:

  • Whole-cell patch-clamp technique was employed to record ionic currents.
  • Dog atrial myocytes were subjected to osmotic challenges (hypotonic and hypertonic solutions).
  • The effects of tyrosine kinase inhibitors (genistein, herbimycin A, tyrphostin 51) and ATPγS on ICl-swelling were assessed.

Main Results:

  • Genistein (50-80 µM) acutely inhibited the reactivation of ICl-swelling without altering cell volume.
  • Daidzein, a non-inhibitor, did not mimic genistein's effect.
  • Intracellular ATPγS blocked genistein's inhibitory effect.
  • Acute herbimycin A and tyrphostin 51 did not inhibit ICl-swelling, but prolonged exposure to herbimycin A did.
  • Genistein's effect was partially reversible upon washout.

Conclusions:

  • Tyrosine protein phosphorylation appears necessary, but not sufficient, for the activation of swelling-induced chloride currents.
  • These findings provide insights into the signaling pathways regulating ICl-swelling.
  • Targeting tyrosine kinases may offer a strategy for modulating cardiac ion channel function.

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...